|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2300069057 |
|
最近更新日期: Date of Last Refreshed on: |
2023-03-06 10:47:16 |
|
注册时间: Date of Registration: |
2023-03-06 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
中性粒细胞与淋巴细胞比值和带状疱疹痛转化相关性的队列研究 |
|
Public title: |
Cohort study of the correlation between neutrophil to lymphocyte ratio and pain transformation in herpes zoster |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
中性粒细胞与淋巴细胞比值和带状疱疹痛转化相关性的队列研究 |
|
Scientific title: |
Cohort study of the correlation between neutrophil to lymphocyte ratio and pain transformation in herpes zoster |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
孙文琴 |
研究负责人: |
孙文琴 |
|
Applicant: |
SUN Wen-qin |
Study leader: |
SUN Wen-qin |
|
申请注册联系人电话: Applicant telephone: |
15873666967 |
研究负责人电话: Study leader's telephone: |
15873666967 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
15873666967@163.com |
研究负责人电子邮件: Study leader's E-mail: |
15873666967@163.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
湖南省常德市人民路818号 |
研究负责人通讯地址: |
湖南省常德市人民路818号 |
|
Applicant address: |
818 Renmin Road, Changde, Hunan |
Study leader's address: |
818 Renmin Road, Changde, Hunan |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
常德市第一人民医院 |
||
|
Applicant's institution: |
The First People's Hospital of Changde City |
||
|
研究负责人所在单位: |
常德市第一人民医院 |
||
|
Affiliation of the Leader: |
The First People's Hospital of Changde City |
||
|
是否获伦理委员会批准: |
是/Yes |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
医-2023-002-01 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
常德市第一人民医院医学伦理委员会 |
||
|
Name of the ethic committee: |
Medical Ethics Committee of the First People's Hospital of Changde City |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2023-01-06 00:00:00 |
||
|
伦理委员会联系人: |
周述香 |
||
|
Contact Name of the ethic committee: |
Zhou Shu-xiang |
||
|
伦理委员会联系地址: |
湖南省常德市人民路818号 |
||
|
Contact Address of the ethic committee: |
818 Renmin Road, Changde, Hunan |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 13787875628 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
|
|
研究实施负责(组长)单位: |
常德市第一人民医院 |
||||||||||||||||||||||
|
Primary sponsor: |
The First People's Hospital of Changde City |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
湖南省常德市人民路818号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
818 Renmin Road, Changde, Hunan |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
常德市第一人民医院 |
||||||||||||||||||||||
|
Source(s) of funding: |
The First People's Hospital of Changde City |
||||||||||||||||||||||
|
Target disease: |
herpes zoster |
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
观察性研究 |
||||||||||||||||||||||
|
Study type: |
Observational study |
||||||||||||||||||||||
|
研究所处阶段: |
回顾性研究 | ||||||||||||||||||||||
|
Study phase: |
Retrospective study |
||||||||||||||||||||||
|
研究设计: |
队列研究 |
||||||||||||||||||||||
|
Study design: |
Cohort study |
||||||||||||||||||||||
|
研究目的: |
NLR与带状疱疹痛转化的关系 |
||||||||||||||||||||||
|
Objectives of Study: |
Relationship between NLR and pain transformation of herpes zoster |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
①符合 《带状疱疹中国专家共识》带状疱疹诊断标准;②入院时处于急性期,发病时间≤ 7 d;③年龄> 18 岁,性别不限 |
||||||||||||||||||||||
|
Inclusion criteria |
① Conform to the diagnostic criteria of herpes zoster in China Expert Consensus on Herpes Zoster;② The patients were in acute stage when they were admitted to hospital, and the onset time was ≤ 7 days;③ Age> 18 years old, regardless of gender |
||||||||||||||||||||||
|
排除标准: |
①长期使用糖皮质激素、免疫抑制剂、免疫增强剂等药物;②伴有精神性疾病、认知功能障碍;③伴有严重免疫缺陷、传染性疾病、血液系统疾病等恶性肿瘤等疾病;④近期有急性感染;⑤妊娠、哺乳期女性。 |
||||||||||||||||||||||
|
Exclusion criteria: |
① Long-term use of glucocorticoids, immunosuppressants, immunopotentiators and other drugs;(2) accompanied with mental disease and cognitive dysfunction;③ accompanied by severe immune deficiency, infectious diseases, hematological diseases and other malignant tumors;④ Acute infection recently;⑤ Pregnant and lactating women. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2023-01-09 00:00:00至 To 2024-12-31 00:00:00 |
征募观察对象时间: Recruiting time: |
从From 2023-03-06 00:00:00 至 To 2023-05-31 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Not yet recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
本研究是回顾性研究,未采用随机分配方法产生随机序列 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
This study is a retrospective study and did not use random assignment to generate random sequences |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
不公开/Private |
|
盲法: |
|
|
Blinding: |
|
是否共享原始数据: IPD sharing |
No |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
不共享数据 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
no |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
病例记录表 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
Case Record Form |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
暂未确定/Not yet |